evipedia.ai
← Back

Serrapeptase for Health & Longevity

Created on 11/04/2026 – Quick Reference based on Evidence Review created using AI4L / Opus 5.5 – Audit

Serrapeptase, a protein-cutting bacterial enzyme, is mainly a supplement for swelling, pain and thick mucus. Single trials show modest relief of ear, nose and throat inflammation and breast engorgement; less swelling after surgery is outweighed by larger trials. Plaque-clearing, long-term anti-inflammatory and brain-protecting claims lack human support. Short-course harms appear rare, though serious lung and skin reactions are documented. It remains an unproven short-term tool, not an established longevity treatment. (Full Review)

Protocol

Pharmaceutical regimen
10 mg three times daily
After meals; original Japanese label dose for 1–2 week courses
Supplement regimen
10–30 mg daily
On an empty stomach, as given by a supplement seller
Dose units
2,000–2,600 units = 1 mg
Labels use activity units; 120,000 units is roughly 46–60 mg
Time to effect
Ear, nose and throat inflammation
7–8 days
In a single trial, symptoms improved faster and more than placebo
Breast engorgement
3 days
In a single trial, breast pain, swelling and hardness improved more than placebo; low-certainty evidence
Swelling after surgery
Days 2–5
Seen in small trials; larger trials outweigh the modest positive ones

Benefits

Contraindications
  • Previous eosinophilic pneumonia
  • Untreated abscess or spreading local infection
  • Previous severe skin reaction (Stevens-Johnson syndrome, blistering disease) to serrapeptase or its combinations
  • Bleeding disorders (hemophilia, von Willebrand disease) or full-dose anticoagulation
  • Pregnancy
    •
Key Interactions
  • Antibiotics (β-lactams: cefotiam, sulbenicillin)
    •
Theoretical (inferred from mechanism)
  • Anticoagulants and antiplatelet drugs (warfarin, apixaban, clopidogrel, aspirin)
  • NSAIDs (diclofenac, ibuprofen)
  • Fibrinolytic enzyme supplements (nattokinase, lumbrokinase)
  • Antiplatelet supplements (fish oil, ginkgo, high-dose vitamin E)
    •

Risk & Side Effects

  • High: [risks_high]
    •
  • Medium: [risks_medium]
    •
  • Low: Drug-induced lung inflammation; severe skin reactions; spread of an existing infection; medication-induced esophageal injury; minor digestive and allergic reactions; increased bleeding tendency; tissue death after self-injection
    •
  • Speculative: Long-term effects of systemic protease exposure
    •

Monitoring

Marker Target Why
CBC with eosinophil count Eosinophils about 0–500 cells/µL Safety check for drug-induced lung inflammation
PT/INR INR about 0.8–1.1 off anticoagulants Bleeding safety check for anticoagulant users
hs-CRP Below 1 mg/L Expected to change; no trial has measured it

Cadence: Baseline blood count, plus PT/INR for anticoagulant users; symptom check at days 3 and 7 of any course; repeat INR within 7 days for anticoagulant users; repeat blood count with eosinophils only if cough, fever, breathlessness or rash appears; optional hs-CRP recheck every 3–6 months for repeated courses

Qualitative Assessment

  • Swelling: visible or measured reduction compared with the other side or with day 1
  • Jaw opening or joint range: easier movement after dental or joint injury
  • Pain: a daily 0–10 rating
  • Mucus and cough: easier coughing up of mucus and fewer coughing bouts
  • Warning signs: new cough, breathlessness, fever, rash, blisters or unusual bruising
Not medical advice. Educational distillation of a single evidence review. Confirm any decision with a qualified clinician, especially in the presence of prescription drugs or chronic conditions.